Phase 2 N=8 Gevokizumab for Active Scleritis
Scleritis
Primary: Number of Participants With at Least a 2-step Reduction or Reduction to Grade 0 in Scleral Inflammation in the Study Eye (or Eyes), According to the National Eye…
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=79 A Study of Pertuzumab in Participants With Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) — 4.9; 0 percentage of participants
Phase 2 N=20 Immunophenotyping of Fresh Stromal Vascular Fraction From Adipose Derived Stem Cells (ADSC) Enriched Fat Grafts
Breast Reconstruction · Contour Irregularities · Volume Insufficiency
Primary: Volume Maintenance — 51.6; 78.9 percentage of graft volume persistency — p=0.310
Phase 2 N=26 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Kidney Cancer
Primary: Progression Free Survival — 9.6 months
Phase 2 N=210 Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Transplant-related Mortality — 18 percentage of participants
Phase 2 N=97 Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children
Type 1 Diabetes
Primary: Comparison of the Time Spent in Hypoglycemia (<70 mg/dl, 3.9 mmol/L) Overnight on Intervention Nights Versus Control Nights, Normalized to an 8-hour Period. — 4.6; 10.1…
Phase 2 N=188 A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.3; 12.4 weeks — p=0.012
Phase 2 N=283 The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis (NASH)
Primary: Hepatic Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) — 50; 23 participants — p=0.0002
Phase 2 N=456 Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
Generalized Anxiety Disorder
Primary: Change From Baseline to Week 8 in the Total Score on the Hamilton Anxiety Scale (HAM-A), as Assessed by the Site-trained Rater — -10.0; -9.3; -9.5 Units on a scale
Phase 2 N=38 Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients
Post-operative Pain · Respiratory Depression
Primary: Measure Any Reduction in the Amount of Opioid Administered to Patients in the Dexmedetomidine Study Arm. — 49; 29; 54; 35 IV morphine equivalency in mg — p=0.03
Phase 2 N=37 AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Overall Response Rate — 2; 0; 0; 1 participants
Phase 2 N=43 Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
Malaria
Primary: Time to Parasite Clearance — 23.63; 44.97; 48.75 Hours
Phase 2 N=9 Canakinumab in Patients With Active Hyper-IgD Syndrome
Mevalonate Kinase Deficiency
Primary: Number of Flares Per Participant During Historical Period and Treatment Period — 5; 0 Number of flares
Phase 2 N=389 Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension
Hypertension
Primary: Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) — -11.53; -10.98; -12.45; -3.69 mmHg
Phase 2 N=75 VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 1 participants